DrugPin

What DrugPin does

Drug-PIN SA, incorporated in 2018 in Lugano, Switzerland (CHE-482.058.077), operates a clinical decision support platform that combines metabolic data, drug-drug interaction analysis, and genomic profiles to help physicians personalize drug prescriptions. The system is built on deep learning, semantic analysis, and machine learning models that reference approximately 19,000 human proteins and 4 million known drug-side-effect-protein associations sourced from the European Medicines Agency, FDA, CPIC/PharmGKB and Open Data. Doctors enter patient data (current drugs, morbidities, lab and genetic data, habits) and receive calculated risk scores for the current therapy, plus ranked alternative medications to reduce trial-and-error prescribing and adverse drug reactions.

The platform is delivered as B2B SaaS accessed via secure web browser or hospital VPN, targeting hospitals, clinics, laboratories, and private-practice physicians. The company employs 11-50 people, is led by founder-CEO and primary investor Renato Della Valle with brother Marco Della Valle as Chairman, and relies on embedded technology partners Datawizard (front-end) and Camelot Biomedical Systems (back-end ML). Only one live deployment is publicly named - University Hospital Sant-Andrea in Rome - with stated plans to roll out additional sites in Italy and Germany. Pricing is not disclosed; customers must request a trial directly. Scientific advisory affiliations with Charité University Berlin, Sapienza University Rome, and University of Liverpool support clinical credibility. No external funding rounds, revenue figures, regulatory clearances, or certifications are evidenced.

Name

DrugPin

Legal name

DRUG-PIN SA

Website

https://drug-pin.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Drug-PIN is a B2B clinical decision support SaaS that combines metabolic, drug-drug interaction, and genomic data using deep learning to help hospitals and physicians personalize prescriptions and reduce adverse drug reactions.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

NAICS

Web Search Portals and All Other Information Services (51929)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

Keywords

• Clinical decision support
• Drug interaction analysis
• Pharmacogenomics software
• Personalized drug prescribing
• Medication risk assessment

Headquarters

HQ city

Roma

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare SaaS Platform Subscription: Drug-PIN appears to operate as a B2B SaaS platform providing healthcare institutions and doctors with access to its intelligent drug prescription analysis system via secure web browser or hospital VPN. The platform is available to hospitals, clinics, labs, and private practice doctors, suggesting institutional subscription-based pricing.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Drug-PIN is an intelligent clinical decision support software platform that combines metabolic data, drug-drug interactions, and genomic profiles to help doctors personalize drug prescriptions. It analyzes patient data against approximately 19,000 human proteins and roughly 4 million known drug-side effect-protein associations using deep learning and semantic analysis to calculate risk scores for current therapies and recommend optimized drug combinations. The platform is delivered to hospitals, clinics, labs, and private practice doctors via secure web browser or hospital VPN.

Product overview

Drug-PIN is a single unified product—a clinical decision support system for personalized drug prescription. The core Drug-PIN platform combines metabolic data, drug-drug interaction analysis, and genomic profiling to support doctors in making optimal prescribing decisions. Doctors access the system via secure web browser or hospital VPN to input patient data (current drugs, morbidities, lab data, genetic data), receive calculated risk scores for current therapies, and fine-tune treatment by exploring alternative medications from a ranked list. The system is designed for post-diagnosis use in hospitals, clinics, labs, and private practice settings.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug-PIN Drug-PIN is an intelligent clinical decision support system that combines metabolic data, drug-drug interactions, and genomic profiles to help doctors make personalized drug prescriptions. Doctors input patient data (current drugs, morbidities, age, gender, habits, lab data, genetic data) via a secure web browser or hospital VPN and receive a calculated risk score for the current therapy plus a ranked list of alternative medications to fine-tune treatment. It is intended for healthcare professionals in hospitals, clinics, labs, and private practice who treat complex or polypharmacy patients.

Quantifiable outcome

• Reduction of trial-and-error prescribing
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• DatawizardcoreImplementation/ SI/ Consulting Partner · 1 January 2018Datawizard handles management, design, and front-end development for Drug-PIN. They are developers of mobile and web digital health applications covering the entire production stack in a single integrated solution, managing big data using hybrid technology approach with Semantic Search Engine, NLP, Machine Learning, Information Retrieval and Ontology-based techniques. Known for strong UX/UI design and market expertise in e-health and pharma, with their most well-known platform being Pharmawizard.
• Camelot Biomedical SystemscoreTechnology or Integration · 1 January 2018Camelot Biomedical Systems handles back-end development for Drug-PIN. They are a team of Machine Learning Specialists, Software Architects and Innovation Experts who have worked in the best artificial intelligence laboratories worldwide. They support Lombardia Region in design and implementation of innovative projects leveraging artificial intelligence and blockchain technologies.
• University Hospital Sant-AndreaflagshipStrategic or Co-development Partner · 1 January 2018University Hospital Sant-Andrea in Rome is a key affiliated hospital where Drug-PIN is currently available for use. This partnership represents a primary implementation site for the drug prescription analysis system.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Oracle Health (formerly Cerner): Major EHR vendor (acquired Cerner) with embedded CDSS for drug-interaction checking and clinical decision support serving hospitals and large health systems globally. Comparable at the workflow layer; offers broad rather than PGx-specialized coverage.
• Wolters Kluwer Clinical Drug Information: Provides Lexicomp, Medi-Span, and related clinical drug information and decision-support tools used by hospitals and clinicians worldwide. Comparable drug-information and prescribing-decision-support offering, but as part of a much broader healthcare content portfolio.
• Epic Systems: Largest US EHR vendor with embedded drug-interaction screening, PGx alerts, and clinical decision support covering the same prescriber workflow Drug-PIN targets. Competes less on AI depth and more on ubiquitous workflow integration and installed base.
• First Databank (Hearst): Leading drug knowledge base provider whose medication-interaction and clinical content is licensed into most major EHRs. Comparable at the underlying drug-interaction intelligence layer that Drug-PIN also relies on, but delivered as data feeds rather than a prescriber-facing CDSS.
• Elsevier Clinical Solutions: Provides ClinicalPath and other evidence-based clinical decision support and drug therapy guidance to hospitals and clinicians. Comparable at the clinical-decision-support layer, though delivered as a broader content portfolio rather than a specialized PGx CDSS.

Direct peers

• Molecular Health: Provides molecular and pharmacogenomic clinical decision support, particularly for oncology and complex therapy selection. Comparable because it fuses molecular/clinical data to recommend drug choices and flag interactions, addressing similar polypharmacy and oncology use cases as Drug-PIN.
• PharmCAT (Stanford): Open-source pharmacogenomic analysis tool from Stanford that interprets PGx test results and generates clinical reports for prescribers. Comparable PGx-focused decision support use case, though academic/free versus Drug-PIN's commercial SaaS model.
• Coriell Life Sciences: Pharmacogenomic interpretation and clinical decision support for medication selection across multiple therapeutic areas. Comparable because it converts PGx test results into actionable prescribing guidance for clinicians and hospitals.
• YouScript: Pharmacogenomics-driven clinical decision support platform that helps prescribers select and dose medications based on patient genetic profiles. Directly comparable product category (PGx-informed prescribing), customer base (physicians and health systems), and value proposition (reducing ADRs and improving drug efficacy).

Emerging players

• Pharmawizard: Italian drug-information platform built by Datawizard (Drug-PIN's own development partner), offering consumer and professional drug information and interaction analysis in Italy. Sister product to Drug-PIN with overlapping drug-data and interaction functionality in the same regional market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DrugPin